Pfizer invests $95m in Valneva

By Rachel Arthur

Pfizer will invest €90.5m ($95m) in French vaccine specialist Valneva, representing 8.1% of Valneva’s share capital. The investment will support the duo’s Lyme disease vaccine partnership.


UK rips up COVID-19 vaccine contract with Valneva

By Rachel Arthur

The UK government accuses Valneva of being in breach of its supply agreement obligations - something the company 'strenuously denies' - as it cancels its COVID-19 vaccine contract.

Valneva-GSK sever vaccine alliance

GSK-Valneva end legacy vaccines partnership

By Ben Hargreaves

GSK and Valneva have come to a mutual early termination agreement, as the former looks to ‘allocate capital to fewer, highest priority areas’.